X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Geron will use the proceeds to fund the potential commercialization of GRN163L in low or intermediate-1 risk myelodysplastic syndromes in the U.S, and potential launch and commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the EU.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 19, 2024
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, administered via intravenous infusion, being developed for relapsed/refractory myelofibrosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in relapsed/refractory AML or higher risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in Relapsed/Refractory AML or Higher Risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in relapsed/refractory AML or higher risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in Relapsed/Refractory AML or Higher Risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
GRN163L (imetelstat) is an investigational, telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and investigated for the treatment of transfusion-dependent anemia with low- to intermediate-1 risk myelodysplastic syndromes.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in Relapsed/Refractory AML or Higher Risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
Geron currently intends to use the net proceeds from this public offering to fund preparatory activities for the potential U.S. commercial launch of GRN163L (imetelstat) in lower risk MDS, and, if approved, to fund the potential U.S. commercial launch of imetelstat.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $227.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
